Facility Details

The goal for the Tissue Engineering Platform is to provide the CRG, PRBB and external researchers with the latests technologies used in the fields of stem cell biology, stem cell differentiation, organoid formation and induced pluripotent stem cells (iPSCs). The Unit is constantly setting up new technologies that are emerging in the above fields. The Tissue Engineering platform works in collaboration with the Biomolecular Screening & Protein Technologies Unit at the CRG to provide CRISPR/Cas9 genome editing technology service. Since 2020, the Tissue Engineering Unit also includes the Histology In-house Service (only for PRBB residents). The Histology In-house Service was established in 2007 to provide the CRG with the histopathological analysis required for analysing tissues from research performed in in vivo models. Studies involving developmental biology, tissue homeostasis and pathology, require an in depth analysis of the morphological and molecular characteristics of the tissues, and the alterations incurred by manipulation. A common tool for these studies is to generate animal models that may recapitulate a specific process or a particular disease. Subsequently, histological and immunohistological analysis are required to identify and characterize changes in the cytoarchitecture and morphology of the tissue. Immunohistochemistry is an essential tool to determine the localization of proteins and RNAs at the tissue and cellular level. In this respect, the main goal of the Histology In-house Service is to perform and optimize histological processing and analysis of the tissue, from experimental animal models and human origin. The service also provides mentoring and training in common histological techniques, in close association with the different groups at the CRG.